Here are five updates on GI companies from the past week:
Piper Jaffray analysts David Amsellem and Sameer Singh believe Valeant's valuation and recent rally is overly optimistic
Axial Biotherapeutics appointed gastroenterologist Alessio Fasano, MD, to its board of directors along with six others.
Researchers working with StemSynergy Therapeutics discovered a class of WNT inhibitors that block colorectal cancer growth with minimal gastrointestinal toxicity.
RedHill Biopharma announced all enrolled patients completed treatment for the phase II study of its irritable bowel syndrome with diarrhea drug.
The FDA approved Gilead Sciences' Vosevi as a second line therapy for chronic hepatitis C.